Aaron T Gerds

List of Publications by Year in Descending Order

95 papers	1,290 citations	17 h-index	33 g-index
101 ext. papers	1,752 ext. citations	3.6 avg, IF	4.21 L-index

#	Paper	IF	Citations
95	Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.. *Oncologist*, **2022**, 27, 228-235	5.7	0
94	Momelotinib reduces transfusion requirements in patients with myelofibrosis.. *Leukemia and Lymphoma*, **2022**, 1-5	1.9	0
93	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.. *Blood Advances*, **2021**,	7.8	2
92	A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis. *Blood*, **2021**, 138, 139-139	2.2	4
91	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 2899-2899	2.2	0
90	Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. *Blood*, **2021**, 138, 3638-3638	2.2	
89	Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**,	4.4	
88	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. *Leukemia and Lymphoma*, **2021**, 62, 1344-1352	1.9	3
87	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. *Blood*, **2021**,	2.2	6
86	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738	1.9	2
85	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 917.e1-917.e9		0
84	Paradigm shift: combination BET and JAK inhibition in myelofibrosis. *Leukemia*, **2021**, 35, 3361-3363	10.7	3
83	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. *Blood Advances*, **2021**, 5, 4361-4369	7.8	2
82	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. *Blood Advances*, **2020**, 4, 5825-5835	7.8	26
81	Survival following allogeneic transplant in patients with myelofibrosis. *Blood Advances*, **2020**, 4, 1965-1973	7.8	23
80	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. *Leukemia and Lymphoma*, **2020**, 61, 1943-1953	1.9	1
79	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. *Blood*, **2020**, 136, 38-39	2.2	2

78	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. *Blood*, **2020**, 136, 41-42	2.2	
77	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. *Blood*, **2020**, 136, 13-14	2.2	1
76	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. *Blood*, **2020**, 136, 33-34	2.2	3
75	Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study. *Blood*, **2020**, 136, 29-31	2.2	5
74	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. *Blood*, **2020**, 136, 33-35	2.2	2
73	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. *Blood*, **2020**, 136, 31-32	2.2	1
72	Rationale for and Results of a Phase I Study of the TGF-□1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. *Blood*, **2020**, 136, 6-8	2.2	6
71	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 472-479	4.7	7
70	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. *Annals of Hematology*, **2020**, 99, 7-19	3	6
69	Genomics of therapy-related myeloid neoplasms. *Haematologica*, **2020**, 105, e98-e101	6.6	10
68	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. *Hematology/ Oncology and Stem Cell Therapy*, **2020**, 13, 32-39	2.7	5
67	Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. *Blood Advances*, **2020**, 4, 4748-4757	7.8	5
66	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. *Blood Advances*, **2020**, 4, 4282-4291	7.8	29
65	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leukemia and Lymphoma*, **2020**, 61, 2811-2820	1.9	3
64	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. *Blood Advances*, **2020**, 4, 5562-5573	7.8	9
63	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. *Blood Advances*, **2020**, 4, 3180-3190	7.8	4
62	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. *Blood Advances*, **2020**, 4, 5246-5256	7.8	21
61	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 262-271	4.7	5

60	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 219-225	2	5
59	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. *Hematology/ Oncology and Stem Cell Therapy*, **2020**, 13, 160-165	2.7	3
58	Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e374-e376	2	1
57	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. *Leukemia Research*, **2019**, 79, 38-44	2.7	20
56	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 104-113	4.2	3
55	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 579-584.e1	2	6
54	A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis. *Blood*, **2019**, 134, 556-556	2.2	31
53	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2696-2696	2.2	1
52	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. *Blood*, **2019**, 134, 4238-4238	2.2	2
51	Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician'S Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count . *Blood*, **2019**, 134, 4175-4175	2.2	10
50	Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib. *Blood*, **2019**, 134, 667-667	2.2	14
49	Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 407-414	3.1	2
48	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595	2.2	
47	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Blood Advances*, **2019**, 3, 2732-2737	7.8	7
46	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. *Blood Advances*, **2019**, 3, 4228-4237	7.8	16
45	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. *Bone Marrow Transplantation*, **2019**, 54, 1281-1286	4.4	17
44	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 775-781	4.4	8
43	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 652-659	13.4	133

42	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1029-1034	4.7	11
41	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. *Blood Cancer Journal*, **2018**, 8, 4	7	21
40	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. *Leukemia and Lymphoma*, **2018**, 59, 363-371	1.9	3
39	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. *Leukemia and Lymphoma*, **2018**, 59, 1195-1201	1.9	10
38	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e463-e468	2	18
37	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075	2.2	
36	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e95-e102	2	3
35	Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. *Leukemia and Lymphoma*, **2018**, 59, 803-812	1.9	10
34	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1831-1839	2.2	67
33	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E49-E52	7.1	9
32	Polycythemia Vera Management and Challenges in the Community Health Setting. *Oncology*, **2017**, 92, 179-189	3.6	8
31	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 767-775	4.7	27
30	The association of histologic grade with acute graft-versus-host disease response and outcomes. *American Journal of Hematology*, **2017**, 92, 683-688	7.1	6
29	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 971-979	4.7	11
28	A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 715-716	4.7	0
27	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. *British Journal of Haematology*, **2017**, 179, 781-789	4.5	36
26	Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times. *Current Hematologic Malignancy Reports*, **2017**, 12, 455-460	4.4	2
25	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. *JAMA Oncology*, **2017**, 3, 1675-1682	13.4	78

24	Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?. *Current Hematologic Malignancy Reports*, **2017**, 12, 582-591	4.4	4
23	Time, timing, and the treatment of diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2016**, 57, 247-248	1.9	
22	Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. *Oncologist*, **2016**, 21, 475-80	5.7	3
21	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1141-1144	4.7	8
20	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. *Blood*, **2016**, 128, 216-216	2.2	16
19	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). *Blood*, **2016**, 128, 4666-4666	2.2	
18	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *Journal of Clinical Oncology*, **2016**, 34, 1864-71	2.2	46
17	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1588-1595	4.7	6
16	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1565-1575	4.7	12
15	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. *Seminars in Hematology*, **2015**, 52, 249-55	4	3
14	Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years. *Leukemia and Lymphoma*, **2015**, 56, 2491-2	1.9	4
13	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood*, **2015**, 125, 1857-65	2.2	118
12	Darbepoetin alfa for anemia with myelodysplastic syndrome. *Expert Review of Hematology*, **2015**, 8, 139-46	2.6	1
11	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. *Blood*, **2015**, 126, 740-740	2.2	3
10	I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. *Current Hematologic Malignancy Reports*, **2014**, 9, 400-6	4.4	5
9	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 89-97	4.7	99
8	Established and novel agents for myelodysplastic syndromes. *Hematology American Society of Hematology Education Program*, **2014**, 2014, 82-9	3.1	6
7	Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. *Leukemia and Lymphoma*, **2014**, 55, 2221-2	1.9	4

6	Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. *Blood*, **2014**, 124, 2642-2642	2.2	1
5	Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 1211-8	4.7	137
4	Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions. *Current Hematologic Malignancy Reports*, **2012**, 7, 292-9	4.4	3
3	Transplantation for myelodysplastic syndrome in the era of hypomethylating agents. *Current Opinion in Hematology*, **2012**, 19, 71-5	3.3	9
2	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 655-62	0.6	
1	Myelodysplastic/myeloproliferative neoplasm overlap syndromes120-128		